Elsevier

Life Sciences

Volume 65, Issues 6–7, 9 July 1999, Pages 627-635
Life Sciences

Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528

https://doi.org/10.1016/S0024-3205(99)00285-4Get rights and content

Abstract

The G protein-coupled cannabinoid receptor subtypes CB1 and CB2 have been cloned from several species. The CB1 receptor is highly conserved across species, whereas the CB2 receptor shows considerable cross-species variations. The two human receptors share only 44% overall identity, ranging from 35% to 82,% in the transmembrane regions. Despite this structural disparity, the most potent cannabinoid agonists currently available are largely undiscriminating and are therefore unsatisfactory tools for investigating the architecture of ligand binding sites. However, the availability of two highly specific antagonists, SR 141716A for the CB1 receptor and SR 144528 for the CB2 receptor, has allowed us to adopt a systematic approach to defining their respective binding sites through the use of chimeric CB1 receptor/CB2 receptor constructs, coupled with site-directed mutagenesis. We identified the region encompassed by the fourth arid fifth transmembrane helices as being critical for antagonist specificity. Both the wild type human receptors overexpressed in heterologous systems are autoactivated; SR 141716A and SR 144528 exhibit classical inverse agonist properties with their respective target receptors. In addition, through its interaction with the CB1 receptor SR 141716A blocks the Gi protein-mediated activation of mitogen-activated protein kinase stimulated by insulin or insulin-like growth factor I. An in-depth analysis of this discovery has led to a modified three-state model for the CB1 receptor, one of which implicates the SR 141716A-mediated sequestration of Gi proteins, with the result that the growth factor-stimulated intracellular pathways are effectively impeded.

References (35)

  • R.D. Bramblett et al.

    Life Sci.

    (1995)
  • G.B. Stefano et al.

    Brain Res.

    (1997)
  • F. Yamaguchi et al.

    Genomics

    (1996)
  • D. Shire et al.

    J.Biol.Chem.

    (1996)
  • D. Shire et al.

    J.Biol.Chem.

    (1995)
  • D. Shire et al.

    Biochim.Biophys.Acta Gene Struct.Expression

    (1996)
  • M. Rinaldi-Carmona et al.

    FEBS Lett.

    (1994)
  • T. Hla et al.

    J.Biol.Chem.

    (1990)
  • M. Bouaboula et al.

    J.Biol.Chem.

    (1997)
  • R. Leurs et al.

    Trends Biochem. Sci.

    (1998)
  • D.B. Houston et al.

    Cell.Signal.

    (1998)
  • M.R. Hoehe et al.

    New Biologist

    (1991)
  • L. Stubbs et al.

    Mammalian Genome

    (1996)
  • P.J.M. Valk et al.

    J.Virol.

    (1997)
  • L.A. Matsuda

    Crit.Rev.Neurobiol.

    (1997)
  • C.M. Gérard et al.

    Biochem.J.

    (1991)
  • L.A. Matsuda et al.

    Nature

    (1990)
  • Cited by (93)

    • Common Receptors for Endocannabinoid-Like Mediators and Plant Cannabinoids

      2015, The Endocannabinoidome: The World of Endocannabinoids and Related Mediators
    • Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities

      2014, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      Several CB2 binding pocket residues have been confirmed for their importance in agonist and antagonist binding, such as S112, W172, Y190, W194, F197, W258, and S285 [17–24]. Moreover, since the third and fifth transmembrane regions of CB2 receptor are playing curial roles in the binding of the vast majority of cannabinoid ligands and consequent signal transduction [17,25], we investigated the possible roles of V113 of TM3 (position 3.32) and L192 of TM5 (position 5.41) in binding with three structurally diverse CB2 ligands: CP-55,940, a non-classical cannabinoids agonist; SR144528, a diarylpyrazole inverse agonist; and XIE95-26, a biamide derivative inverse agonist [26] (Supplemental Fig. 1). A CB2 homology model was constructed from the antagonist-bound A2A receptor (3EML.

    • Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes

      2014, Cell Calcium
      Citation Excerpt :

      For this purpose, we have first tested the effects of established antagonists of CB1 and CB2 receptors on the AEA inhibition of shortening amplitudes in cardiomyocytes. Two structurally different CB1 receptor antagonists (AM251 with a Ki of 7.5 nM [26]; Fig. 2A and SR141716 with a Ki of 1.8 nM [27]; Fig. 2B) and two CB2 receptor antagonists (AM630 with a Ki of 32.1 nM [26] and SR144528 with Ki of 0.6 nM [27]) were tested. At 300 nM concentration, these antagonists were not able to reverse the inhibitory effect of AEA on the shortenings amplitudes of cardiomyocytes (n = 8–12, ANOVA, P > 0.05).

    • Brain PET Imaging in the Cannabinoid System

      2014, Imaging of the Human Brain in Health and Disease
    • Probing the interaction of SR141716A with the CB1 receptor

      2012, Journal of Biological Chemistry
      Citation Excerpt :

      Because Phe-3797.35 was identified as a residue critical for SR141716A binding in this study (Table 1), all the receptor residues within 20 Å of Phe-3797.35, whose aromatic ring was positioned toward the TM core, were defined as the binding site. This region adequately covered all the reported SR141716A contact residues (6, 14, 15), including Phe-2003.36, Trp-2795.43, and Trp-3566.48, as well as the TM4-EC2-TM5 segment important for SR141716A binding (16, 17). For the GOLD docking experiment, we used the pre-defined default GOLD generic algorithm settings.

    • Fluorinated cannabinoid CB2 receptor ligands: Synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives

      2011, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      Raitio et al. synthesized a new series of CB2 inverse agonists with responses comparable to SR144528,34,35 based on the structure of 2-oxoquinoline JTE-907 (29, Table 2, Supplementary data) in which the piperonylamide end has been replaced with a variety of aromatic amide structures (32–37, Table 2, Supplementary data).34 Several other classes of compounds, including tricyclic pyrazoles,30–32 sulfamoyl benzamides,36 triarylbis-sulfones,37 and arylsulfonamide,38 have been synthesized and reported to be CB2 receptor ligands. However, among all the classes of CB2 ligands, 2-oxoquinoline derivatives appear to be the most efficient inverse agonists, with high binding affinity and selectivity for CB2 receptor.34,35

    View all citing articles on Scopus
    View full text